| Drug Name |
Sodium zirconium cyclosilicate |
| Drug ID |
BADD_D02521 |
| Description |
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent.[L2933] It is administered orally and is odorless, tasteless, and stable at room temperature.[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.[L2933] The treatment effect was maintained for up to 12 months.[L2933] |
| Indications and Usage |
Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients.[L12822,F130] |
| Marketing Status |
approved; investigational |
| ATC Code |
V03AE10 |
| DrugBank ID |
DB14048
|
| KEGG ID |
D10727
|
| MeSH ID |
C000597310
|
| PubChem ID |
92042806
|
| TTD Drug ID |
D03AZK
|
| NDC Product Code |
65977-0132; 0310-1105; 50090-6502; 0310-1110; 50090-6501; 0310-2111 |
| UNII |
D652ZWF066
|
| Synonyms |
sodium zirconium cyclosilicate | ZS-9 compound | Lokelma |
